Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 1 of 1 for:    NCT03928314
Previous Study | Return to List | Next Study

Study of ORIC-101 in Combination With Anticancer Therapy

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03928314
Recruitment Status : Recruiting
First Posted : April 26, 2019
Last Update Posted : August 17, 2020
Sponsor:
Information provided by (Responsible Party):
Oric Pharmaceuticals

Brief Summary:
The purpose of this study is to establish the recommended Phase 2 dose (RP2D), safety, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary antitumor activity of ORIC-101 in combination with nab-paclitaxel or other anticancer therapies when administered to patients with advanced or metastatic solid tumors.

Condition or disease Intervention/treatment Phase
Solid Tumor Drug: ORIC-101 Drug: Nab-paclitaxel Phase 1

Detailed Description:

ORIC-101 is a small molecule GR antagonist being developed for the treatment of patients with solid tumor malignancies. Mechanistically, ORIC-101 inhibits GR transcriptional activity and blocks the pro-survival signals mediated by the activated nuclear receptor.

This is an open-label, uncontrolled, multicenter, dose-finding study to assess the safety and preliminary antitumor activity of ORIC-101 in combination with nab-paclitaxel or other anticancer therapy in patients with advanced or metastatic solid tumors. The study will begin with dose finding in combination initially with nab-paclitaxel in patients with various solid tumors (Part I); additional dose expansion cohorts in specific tumor types with nab-paclitaxel (Part II) or with other anticancer therapies may be evaluated through protocol amendment(s).

The study will first evaluate intermittent administration (5 days on, 2 days off for 21 days) of ORIC-101 followed by continuous administration (daily for 21 days) in combination with nab-paclitaxel using a standard 3+3 dose escalation design.

In Part II, patients will be enrolled across four cohorts of advanced or metastatic disease:

  • pancreatic ductal adenocarcinoma (PDAC)
  • ovarian cancer
  • triple negative breast cancer (TNBC)
  • other solid tumors

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 174 participants
Allocation: Non-Randomized
Intervention Model: Sequential Assignment
Intervention Model Description: Standard 3+3 dose escalation design, followed by dose expansion
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: An Open-label Phase 1b Study of ORIC-101 in Combination With Anticancer Therapy in Patients With Advanced or Metastatic Solid Tumors
Actual Study Start Date : May 2, 2019
Estimated Primary Completion Date : May 2022
Estimated Study Completion Date : May 2022

Resource links provided by the National Library of Medicine

Drug Information available for: Paclitaxel

Arm Intervention/treatment
Experimental: Dose Escalation (Part I)
ORIC-101 dosed orally, once per day, for 5 or 7 days/week in combination with nab-paclitaxel (75 or 100 mg/m2 on Days 1, 8, and 15) of each 28-day cycle.
Drug: ORIC-101
ORIC-101 once daily, 5 or 7 days/week, for 21 days of each 28-day cycle

Drug: Nab-paclitaxel
75 or 100 mg/m2 Days 1, 8, and 15 of each 28-day cycle

Experimental: Dose Expansion (Part II)
RP2D dose
Drug: ORIC-101
ORIC-101 once daily, 5 or 7 days/week, for 21 days of each 28-day cycle

Drug: Nab-paclitaxel
75 or 100 mg/m2 Days 1, 8, and 15 of each 28-day cycle




Primary Outcome Measures :
  1. Part I: Recommended Phase 2 Dose (RP2D) [ Time Frame: 12 months ]
    RP2D as determined by 3+3 dose escalation design

  2. Part II: Objective Response Rate (ORR) [ Time Frame: 18 months ]
    Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 and assessed by Blinded Independent Central Review (BICR)


Secondary Outcome Measures :
  1. Part I: Maximum plasma concentration (Cmax) [ Time Frame: 28 Days ]
    PK of ORIC-101 in combination with nab-paclitaxel

  2. Part I: Time of maximum observed concentration (Tmax) [ Time Frame: 28 Days ]
    PK of ORIC-101 in combination with nab-paclitaxel

  3. Part I: Area under the curve (AUC(0-t)) [ Time Frame: 28 Days ]
    PK of ORIC-101 in combination with nab-paclitaxel

  4. Parts I and II: Number of Participants with Adverse Events [ Time Frame: 36 months ]
    Safety and tolerability of ORIC-101 in combination with nab-paclitaxel

  5. Parts I and II: Number of Participants with Abnormal Laboratory Values [ Time Frame: 36 months ]
    Safety and tolerability of ORIC-101 in combination with nab-paclitaxel

  6. Parts I and II: Number of Participants with Abnormal 12-lead ECG [ Time Frame: 36 months ]
    Safety and tolerability of ORIC-101 in combination with nab-paclitaxel

  7. Parts I and II: Number of Participants with Abnormal Vital Signs [ Time Frame: 36 months ]
    Safety and tolerability of ORIC-101 in combination with nab-paclitaxel

  8. Part I: Number of Participants with Antitumor Activity [ Time Frame: 36 months ]
    Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 criteria

  9. Part II: Duration of Response (DOR) [ Time Frame: 36 months ]
    Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 and assessed by Blinded Independent Central Review (BICR)

  10. Part II: Progression-Free Survival (PFS) [ Time Frame: 36 months ]
    Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 and assessed by Blinded Independent Central Review (BICR)

  11. Part II: Overall Survival (OS) [ Time Frame: 36 months ]
    Time from first dose of ORIC-101 in combination with nab-paclitaxel to death

  12. Part II: Investigator-assessed ORR [ Time Frame: 36 months ]
    Response Evaluation Criteria in Solid Tumors (RECIST) 1.1


Other Outcome Measures:
  1. Parts I and II: Number of Participants with GR Expression by IHC [ Time Frame: 36 months ]
    Level of GR expression by IHC in tumor tissue samples



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria (Part I):

  • Advanced or metastatic solid tumor, with the exception of neuroendocrine tumors that secrete adrenocorticotropic hormone (ACTH) or corticotropin-releasing hormone (CRH), for which no alternative effective standard therapy is available or for which standard therapy is considered unsuitable or intolerable
  • Measurable disease (ie, presenting with at least one measurable lesion per RECIST 1.1)
  • Radiographic evidence of a lesion that may be safely biopsied by core needle biopsy
  • For patients with treated, stable CNS metastases that are asymptomatic: no evidence of progression for at least 4 weeks after CNS-directed treatment as determined by clinical examination and brain imaging. Patients must not require steroids
  • ECOG performance status 0 or 1
  • Life expectancy of at least 3 months
  • Available archival FFPE tissue for submission to central laboratory
  • Male: must agree to birth control requirements and Female: not pregnant, breastfeeding, and meets requirements regarding women of child-bearing potential
  • Capable of giving signed informed consent
  • Agreement and ability to undergo two on-study biopsies, as follows, through a procedure that is deemed to be clinically feasible and not carry significant risk:

    • one pre-treatment tumor biopsy obtained prior to dosing; and
    • one post-treatment tumor biopsy during Cycle 2

Exclusion Criteria (Part I):

  • Any other current or active malignancy
  • Grade 2 or higher peripheral neuropathy
  • Known human immunodeficiency virus (HIV) infection
  • Major surgery within 21 days prior to Cycle 1 Day 1 or incomplete recovery from adverse effects resulting from such procedure
  • Females: history of unexplained vaginal bleeding in the 8 weeks prior to planned study treatment
  • History of Cushing's syndrome or adrenal insufficiency
  • Other concurrent serious uncontrolled medical, psychological, or addictive conditions that may interfere with planned study treatment or adherence to protocol
  • Prior or current treatment with ORIC-101 or any other GR antagonist (eg, mifepristone, relacorilant)
  • Current or requirement for chronic use of systemic corticosteroids with the exception of inhaled, topical, intraocular, intranasal, or intraarticular corticosteroids.
  • Current or expected on-study treatment with specified strong CYP3A4 inhibitors or inducers
  • Treatment with another investigational medicinal product (within 3 weeks prior to starting study treatment)
  • Receiving any other anticancer therapy, radiotherapy, or herbal (alternative) medicines within 7 days prior to starting study treatment
  • Use of hormone replacement therapy by females
  • Current enrollment in any other therapeutic clinical study involving an investigational study treatment
  • Presence of Hepatitis B surface antigen at screening
  • Positive Hepatitis C antibody test result at screening or within 3 months prior to starting study treatment
  • Positive Hepatitis C RNA test result at screening or within 3 months prior to first dose of study treatment
  • Unacceptable laboratory criteria:

    • ANC <1500 cells/mm3 (1.5 × 103 cells/mm3)
    • Platelets <100,000 /µL (100 × 109 /L)
    • Hemoglobin <9.0 g/dL (90 g/L)
    • Albumin <3.0 g/dL (30 g/L)
    • AST (SGOT) or ALT(SGPT) >2.5 × ULN
    • AST (SGOT) or ALT (SGPT) >2.5 and ≤5.0 × ULN is acceptable for patients with liver metastases
  • Bilirubin >1.5 × ULN:

    • Isolated bilirubin >1.5 × ULN is acceptable if bilirubin is fractionated and direct bilirubin <35% of total bilirubin
    • Bilirubin >1.5 and ≤3.0 × ULN is acceptable for patients with known Gilbert's disease
  • QTcF >450 msec for males; QTcF >470 msec for females; or QTcF >480 msec for those with bundle branch block (BBB)
  • Consumption of Seville oranges, grapefruit or grapefruit juice, pomelos, exotic citrus fruits, grapefruit hybrids, or fruit juices containing these fruits from 10 days before the start of study treatment
  • Sensitivity to any of the study treatments, or components thereof, or drug or other allergy that, in the opinion of the investigator, contraindicates participation in the study.
  • Any other condition or circumstance (eg, familial, sociological, inability to swallow oral study drug) that, in the opinion of the investigator, may interfere with protocol compliance or contraindicates participation in the study.

Expansion Cohorts Part II Inclusion Criteria:

  • PDAC: Advanced or metastatic PDAC previously treated with and progressed on a fluoropyrimidine-based regimen and a taxane-containing chemotherapy regimen (eg, gemcitabine + nab-paclitaxel). Pancreatic neuroendocrine tumors, lymphoma of the pancreas, acinar pancreatic cancer, or ampullary cancer are not eligible.
  • Ovarian Cancer: Advanced or metastatic high grade serous or endometrioid epithelial ovarian, primary peritoneal, fallopian tube cancer or ovarian carcinosarcoma, previously treated with and progressed on a taxane-containing chemotherapy regimen; clear cell, mucinous and borderline histologic subtypes are not eligible; must have received at least one line of therapy with evidence of cancer progression within 6 months after the last dose of platinum-based therapy (ie, having a platinum-free interval of <6 months [platinum resistant]), or progressive disease during or immediately after primary platinum-therapy, (ie, platinum refractory).
  • TNBC: Advanced or metastatic ER-negative, PR-negative, HER2-negative primary breast cancer previously treated and progressed on a taxane-based chemotherapy regimen; no previous or synchronous second breast cancer, unless also confirmed ER-, PR- and HER2-negative; must have received at least one line of therapy in the metastatic setting.
  • Other Solid Tumor: Other advanced or metastatic solid tumor previously treated with and progressed on a taxane-based chemotherapy regimen, with the exception of metastatic colorectal cancer, primary brain tumors, and neuroendocrine tumors that secrete ACTH or CRH; must have received no more than 4 prior lines of cytotoxic or myelosuppressive therapy

Other Key Inclusion Criteria:

  • At least 18 years of age
  • ECOG performance status 0 or 1
  • Measurable disease as assessed centrally using RECIST 1.1
  • Treated, stable CNS metastases must be asymptomatic and must not require steroids
  • Agreement and ability to undergo two on-study biopsies, one pre-treatment obtained prior to dosing and during Cycle 2
  • Adequate organ function as defined by the following criteria:

    • ANC ≥1500 cells/mm3 (1.5 × 103 cells/mm3)
    • Platelets ≥100,000 /µL (100 × 109 /L)
    • Hemoglobin ≥9.0 g/dL (90 g/L)
    • Albumin ≥3.0 g/dL
    • AST (SGOT) or ALT (SGPT) ≤2.5 × ULN, ≤5.0 × ULN for patients with liver metastases
    • Bilirubin ≤1.5 × ULN; patients with a known history of Gilbert's syndrome and/or isolated elevations of indirect bilirubin are eligible
    • QTcF ≤480 msec
  • Ability to swallow ORIC-101 intact without chewing or crushing the capsules or tablets
  • Adequate gastrointestinal absorption. If the patient has undergone gastric bypass surgery and/or surgery of gastrointestinal or hepatobiliary tract, the patient must demonstrate adequate absorption as evidenced by albumin ≥3.0 g/dL, controlled pancreatic insufficiency (if present), and lack of evidence of malabsorption

Expansion Cohorts Part II Exclusion Criteria:

  • Any other current or active malignancy
  • Prior or current treatment with ORIC-101 or any other GR antagonist (eg, mifepristone, relacorilant)
  • Concurrent treatment with any other anticancer therapy including chemotherapy, hormonal therapy, immunotherapy, radiotherapy, chemoembolization, targeted therapy, or an investigational agent within 28 days prior to Cycle 1 Day 1
  • Major surgery or radiotherapy within 21 days prior to Cycle 1 Day 1 or incomplete recovery from adverse effects resulting from such procedures; palliative radiotherapy within 1 week of Cycle 1 Day 1
  • Systemic, inhaled, or prescription strength topical corticosteroids within 21 days prior to Cycle 1 Day 1; short courses (≤5 days) for non-cancer-related reasons are allowed if clinically required
  • Grade 2 (moderate) or higher peripheral neuropathy per CTCAE v5.0; patients with mild peripheral neuropathy may be eligible at the discretion of the investigator in consultation with ORIC
  • All other toxicities from prior therapy (except alopecia) that have not resolved to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE) v5.0 ≤ Grade 1
  • Females: history of unexplained vaginal bleeding in the 8 weeks prior to Cycle 1 Day 1 (given potential for ORIC-101 to exacerbate such bleeding)
  • Females: use of hormone replacement therapy; hormone replacement therapy must be discontinued to allow for confirmation of postmenopausal status
  • History of Cushing's syndrome or adrenal insufficiency
  • Current (within 10 days prior to Cycle 1 Day 1) or expected on-study treatment with specified strong CYP3A4 inhibitors or inducers
  • Known human immunodeficiency virus (HIV) infection, unless patient is healthy and has a low risk of AIDS-related outcomes
  • Presence of Hepatitis B surface antigen (HBsAg) at screening
  • Positive Hepatitis C (HCVAb) antibody test result at screening or within 3 months prior to Cycle 1 Day 1. NOTE: Patients with positive HCVAb due to prior resolved disease can be enrolled if a confirmatory negative Hepatitis C RNA test is obtained
  • Positive Hepatitis C RNA test result at screening or within 3 months prior to Cycle 1 Day 1. NOTE: Test is optional and patients with negative HCVAb test are not required to also undergo Hepatitis C RNA testing

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03928314


Contacts
Layout table for location contacts
Contact: Maureen Duff, PharmD 650-388-5600 maureen.duff@oricpharma.com
Contact: Edna Chow Maneval, PhD 650-388-5600 edna.chowmaneval@oricpharma.com

Locations
Layout table for location information
United States, California
Stanford Cancer Institute Recruiting
Palo Alto, California, United States, 94304
Contact: Aja Macias    650-721-4090    amacias2@stanford.edu   
Principal Investigator: Sukhmani Padda, MD         
UCSF Helen Diller Family Comprehensive Cancer Center Recruiting
San Francisco, California, United States, 94115
Contact: Shabana Akramy    415-514-6674    shabana.akramy@ucsf.edu   
Principal Investigator: Pamela Munster, MD         
United States, Florida
Florida Cancer Specialists & Research Institute Recruiting
Lake Mary, Florida, United States, 32746
Contact: Jessica Keville    407-804-6133    jessica.keville@flcancer.com   
Principal Investigator: Shekeab Jauhari, MD         
Florida Cancer Specialists & Research Institute Recruiting
Sarasota, Florida, United States, 34232
Contact: Heather Williams    941-377-9993    hmwilliams@flcancer.com   
Principal Investigator: Manish Patel, MD         
United States, Oregon
Oregon Health & Science University Recruiting
Portland, Oregon, United States, 97239
Contact: Emily Moher    503-418-9324    moher@ohsu.edu   
Principal Investigator: Shivaani Kummar, MD         
United States, Texas
NEXT Oncology Recruiting
San Antonio, Texas, United States, 78229
Contact: Dominique McReynolds    210-580-9516    dmcreynolds@nextoncology.com   
Principal Investigator: Raghad Karim, MD         
United States, Virginia
Virginia Cancer Specialists, PC Recruiting
Fairfax, Virginia, United States, 22031
Contact: Melissa Hackmaster    703-208-9280    melissa.hackmaster@usoncology.com   
Principal Investigator: Alex Spira, MD, PhD         
Sponsors and Collaborators
Oric Pharmaceuticals
Investigators
Layout table for investigator information
Study Director: Pratik S. Multani, MD Oric Pharmaceuticals
Layout table for additonal information
Responsible Party: Oric Pharmaceuticals
ClinicalTrials.gov Identifier: NCT03928314    
Other Study ID Numbers: 101-18101
First Posted: April 26, 2019    Key Record Dates
Last Update Posted: August 17, 2020
Last Verified: August 2020

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Oric Pharmaceuticals:
GR antagonist
Glucocorticoid receptor antagonist
Additional relevant MeSH terms:
Layout table for MeSH terms
Paclitaxel
Albumin-Bound Paclitaxel
Antineoplastic Agents, Phytogenic
Antineoplastic Agents
Tubulin Modulators
Antimitotic Agents
Mitosis Modulators
Molecular Mechanisms of Pharmacological Action